After disclosing data from the phase II Herald study, Aligos Therapeutics Inc. may sign a partner to help advance ALG-055009, a thyroid hormone receptor (THR) beta agonist, in subjects with metabolic ...
As the nation awaits to join the chorus singing hosannas to a new president—whoever that may be—to be announced in the course of the day, he will be instantly coronated with the thorny crown of the ...